Abstract
Preeclampsia is a major cause of maternal, fetal and neonatal morbidity/mortality. Levels of serum sFlt-1 (soluble fms-like tyrosine kinase-1) are increased and levels of serum PlGF (placental growth factor) are decreased in pregnant women developing or having diagnosed preeclampsia/eclampsia/HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. Measurement of the sFlt-1/PlGF ratio is used as additional tool in preeclampsia diagnosis. However, the utility of the sFlt-1/PlGF ratio in guiding physicians' surveillance and treatment decisions for patients with suspicion of preeclampsia has not yet been evaluated in routine clinical practice. PreOS assessed the influence of the sFlt-1/PlGF test result on physicians' clinical decision-making regarding hospitalization, treatment and monitoring of patients who were considered likely to develop preeclampsia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
